FDA Webview

Free FDA Notices

Workshop Slated on Osteoporosis Drug Development


Federal Register Notice: CDER’s Division of Bone, Reproductive, and Urologic Products will hold a public workshop 11/4 entitled “Osteoporosis Drug Development: Moving Forward.” Its purpose is to seek input from experts on scientific issues important to clinical development of drugs and therapeutic biologics intended to treat osteoporosis. Attendees will discuss potential surrogate endpoints and the endpoints' ability to predict clinical benefit. The workshop will be held from 8 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, in Sections B and C of the Great Room (Rm. 1503), Silver Spring, MD. Contact Samantha Bell, (301) 796-9687, email: Samantha.Bell@fda.hhs.gov. To view this notice, click here.